OUR LEADERSHIP
… is focused on developing breakthrough treatments that will repair, rewire and heal the brain.
Ahmad Doroudian, PhD
Chief Executive Officer & Director
- 20+ years experience as a Pharma CEO in finance, including M&A, and multiple IPOs, integration of pharmaceutical operations (Whitehall Robbins, Rhone Polenc, Boehringer, Aventis)
- Founder of Merus Labs (NASDAQ: MSLI), sold for $300 M+ in 2017
- Acquisition, integration, tech transfer and management of branded pharmaceutical products Enablex®/Emselex®, Entrophen®, Sandomigran®, Sintrom®, Vancocin®, Zaditen®
Hooshmand Sheshbaradaran, PhD
Chief Operating Officer
- 30+ years senior pharma executive with experience in global drug development, marketing, business strategy, operations, licensing and M&A
- Senior executive roles at Pharmacia/Pfizer, Roche, Zeneus/Cephalon, Niiki Pharma, Psioxus
- Development of Camptosar®, Ellence®, Emcyt®, Sutent® and Vidaza®.
Moira Ong, CPA, CA
Chief Financial Officer
- 20+ years experience in financial reporting, compliance and audit.
- Managed the integration of the supply chain management and accounting for Vancocin, Enablex®/Emselex®, acquired from Novartis, by Merus Labs International Inc. (formerly NASDAQ: MSLI)
- Previously at Grant Thornton, Deloitte & Touche
Scott Rudge, PhD
Head CMC
- Founded CMC development expert services group in 2004, has worked on over 200 projects for all molecule/therapy classes since
- Site Director & VP Operations for FeRx; increasing management responsibility at NIST, Synergen, Amylin
- PhD in Chemical Engineering from Purdue and author of multiple peer reviewed articles, book chapters and an award-winning textbook
Abdi Ghaffari, PhD
Head Preclinical & Toxicology
- 15+ years pharma executives with experience in nonclinical pharmacology and toxicology in fields of neuropsychiatric disorders, oncology, and respiratory infection.
- Senior scientist roles at PulmoNOx, Beyond Air, Novateur, and Tika Therapeutics.
OUR ADVISORS / COLLABORATORS
Douglas Drysdale
Douglas Drysdale
A globally recognized thought leader and transformative strategist with over 35 years in healthcare and pharmaceuticals; formerly CEO Cybin Inc; CEO Tedor Pharma Inc; Chairman & CEO Pernix Therapeutics; Founder & CEO Alvogen Inc. See BetterLife news and Bio.
Daniel Carcillo
Daniel Carcillo
Nine-year professional NHL, two-time Stanley Cup winner; Founder Chapter 5 Foundation; Member “Decriminalize Nature”
National Advisory Board; Founder & CEO Wesana Health; Board member “Heroic Hearts” military veterans’ project. See Wikipedia Daniel Carcillo and Daniel Carcillo webpage.
Dr. Adam Halberstadt
Dr. Adam Halberstadt
Associated Professor Psychiatry
UC San Diego
Dr. John McCorvy
Dr. John McCorvy
Assistant Professor Dept. Neurobiology
Medical College of Wisconsin
Dr. Argel Aguilar-Valles
Dr. Argel Aguilar-Valles
Assistant Professor Dept. Neuroscience
Carlton University
Ahmad Doroudian, PhD
- 20+ years experience as a Pharma CEO in finance, including M&A, and multiple IPOs, Integration of pharmaceutical operations (Whitehall Robbins, Rhone Polenc, Boehringer, Aventis)
- Founder of Merus Labs (NASDAQ: MSLI), sold for $300 M+ in 2017
- Acquisition, integration, tech transfer and management of branded pharmaceutical products Enablex®/Emselex®, Entrophen®, Sandomigran®, Sintrom®, Vancocin®, Zaditen®
Robert Metcalfe
- Served as president, chief executive officer, lead director, chairman and committee member on numerous publicly listed natural resource and industry company corporate boards in Canada, the USA, England, South America and Africa
- Senior partner with the law firm, Lang Michener LLP, for 20 years
- Engaged in numerous acquisitions, divestitures, corporate reorganizations, financings and corporate improvements, as well as serving on numerous special committees across many sectors
Ralph Anthony Pullen
- Investment banker in the healthcare and biotechnology industry sectors
- Instrumental in the creation and funding of MDS Capital Corp., Canada’s largest venture capital fund dedicated to the life sciences, now known as Lumira Capital where he served as a board member
Dr. Steven Sangha
- 25+ years of experience in investment banking, business development and asset management.
- Extensive experience with public company governance, compliance and finance has led Dr. Sangha to run a successful private fund family office.
- Interest in the biotechnology and mining industries has allowed positive growth for early-stage companies with Dr. Sangha’s consummate efforts in assessment, development and financial support.
- Doctorate of Dental Surgery (University of Western Ontario, London, Ontario) and a Bachelor of Pharmaceutical Science (University of British Columbia, Vancouver, British Columbia).
